Led · Series A · Sep 2025

Nutrium, founded in 2015 in Portugal, offers Nutrium Care, a comprehensive corporate nutrition benefit that pairs 1:1 dietitian support with proactive digital coaching. The platform serves millions of patients and links them to a network of more than 350,000 registered dietitians across over 90 countries. Corporate clients report a three-times return on investment, a 5% average weight reduction within four months, reduced prescription drug usage, and higher employee productivity. Nutrium’s solution is positioned as a lower-cost, higher-adherence alternative to GLP-1 medications for obesity management. The company recorded 400% revenue growth in the last year, underscoring rapid market adoption. With the new capital, Nutrium plans to expand its U.S. presence and forge additional partnerships with health plans and consultants to scale its nutrition care offering.

Participated · Series E · Sep 2024

Inflammatix is reimagining infectious-disease diagnostics by using proprietary host-response biomarkers and machine learning to measure gene expression patterns from a finger-stick blood sample. Its sample-to-answer Myrna instrument platform delivers results in under 30 minutes and is being paired with the ViraBac EZ test, which tells physicians whether an infection is bacterial or viral so they can prescribe antibiotics appropriately. The company’s initial focus areas are acute infections and sepsis, large markets where faster, more precise information can improve outcomes and curb antibiotic resistance. Inflammatix’s technology aims to reduce the estimated 30 % of antibiotics that are inappropriately prescribed in U.S. outpatient settings each year. Commercialization efforts are currently supported by non-dilutive government funding and venture backing from Khosla Ventures, Northpond Ventures, Stanford StartX Fund, Think.Health Ventures, and OSF Ventures. A BARDA contract worth up to $72 million, if all options are exercised, underpins ongoing product development. The latest tranche of BARDA financing brings additional resources to finalize the testing system and move it toward market launch.

Participated · Series C · Aug 2024

Caresyntax offers a vendor-neutral precision surgery platform led by CEO Dennis Kogan. Its proprietary software and AI captures and analyzes large volumes of video, audio, images, device, clinical and operational data in and around the operating room to deliver actionable insights, meta-data and real-world evidence. The software and automation platform can be used live during procedures and accessed by users outside the OR via secured dedicated cloud and telehealth links. The platform aims to help surgeons and care teams improve patient outcomes, enable hospital administrators to use resources more efficiently, assist medical device companies to advance products, and support insurers in understanding and controlling risks and enabling value-based contracts. Caresyntax serves over 30,000 surgical professionals across more than 3,000 operating rooms worldwide. The company raised $180M in Series C financing and intends to use the funds to expand operations and its development efforts. Caresyntax provides a digital surgery platform that uses proprietary software and artificial intelligence to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. The platform delivers actionable insights for care teams and longer-term analytics for stakeholders such as surgeons, and offers virtual, real-time access to outside experts. Caresyntax's software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company plans to use new funds to continue developing its platform and to advance new data solutions that support value-based care providers. The product emphasis is on improving patient outcomes through immediate and longer-term insights derived from real-world OR data. The company was founded by Dennis Kogan and Björn von Siemens. Caresyntax provides an enterprise-grade digital surgery platform that uses proprietary software and AI to analyze large volumes of video, audio, images, device, clinical, and operational data in and around the operating room. Its platform delivers real-world evidence that care teams can use live during procedures via a telehealth link and post-procedure for benchmarking and improvement. Hospitals can use the platform to manage surgical resources more efficiently, medical device companies can advance products, and insurers can better understand risk. The software is used in more than 4,000 operating rooms worldwide and supports surgical teams in over two million procedures per year. The company announced the acquisition of Syus at the close of 2019, extending its hospital footprint and analytics capabilities. Caresyntax intends to use the new funding to accelerate expansion in key markets, further R&D of its AI analytics, build out its platforms, and grow its employee base. caresyntax provides surgical intelligence and automation solutions that leverage IoT, analytics and AI to integrate data from medical devices, EHRs and other OR sources into a unified platform. Its offerings automate clinical and operational decision support for surgical teams and support outcome contributors across risk-bearing contracts. The company says its technologies are used in more than 7,000 operating rooms worldwide and support over 10 million procedures per year. Recent partnerships with organizations including Mitsubishi’s MC Healthcare, Barco Healthcare, Insel Gruppe AG and University of Wisconsin–Madison aim to expand R&D and global reach. caresyntax plans to use new capital to accelerate domestic and international growth and to further develop and deploy its surgical intelligence and automation technologies. The company works with providers, insurers and device vendors to inform device improvements, support data-driven underwriting and enable value-based contracting. Caresyntax provides a vendor-neutral platform that aggregates structured and unstructured data from operating room devices, electronic health records and other sources into unified dashboards for surgeons and hospital decision makers. Its offerings include PRIME365 OR integration and qvident surgical performance management software, which aim to reduce documentation time, automate workflows, and generate quality data for training and decision support. The company emphasizes granular analysis of surgical variation to recommend fixes that reduce readmissions, improve patient safety and streamline clinical workflows. Caresyntax reports an installed base of more than 6,000 operating rooms, supports over 10 million procedures per year and generates roughly 100 petabytes of high-fidelity data annually. It was launched in 2013 in Germany and established full-time North American operations and a headquarters in Boston in October. The company says it will use the new financing to grow its U.S. business and to develop machine learning and value-added applications for surgical risk management.

Participated · Series D · Jul 2024

CatalYm's lead product, visugromab (CTL-002), is a humanized monoclonal antibody engineered to neutralize tumor-derived GDF-15 and thereby reverse immunosuppression and resistance to checkpoint inhibitors. The company reported impressive Phase 1/2a (GDFATHER) data showing deep, durable anti-tumor activity in combination with nivolumab, including several complete responses in NSCLC, urothelial cancer and hepatocellular carcinoma. CatalYm plans a broad Phase 2b development program, expanding into randomized Phase 2b studies in select checkpoint‑naïve frontline and second‑line treatment settings and preparing to launch further randomized, controlled studies in multiple indications in the first half of 2025. The company completed an oversubscribed $150 million Series D to fund that expansion. Founded in 2016 with early support from Forbion Ventures Fund III and BGV, CatalYm is positioning visugromab as a new class of cancer immunotherapy to address resistance across high‑need solid tumor indications. CatalYm’s lead program is visugromab, a humanized monoclonal antibody engineered to neutralize tumor-produced Growth Differentiation Factor‑15 (GDF‑15) and thereby enhance immune cell infiltration and antitumor activity. The company is expanding Phase 2 development after encouraging efficacy and durability signals in Phase 1 and continued positive responses in the ongoing GDFATHER-2 trial. GDFATHER-2 evaluates visugromab in combination with an anti‑PD‑1 antibody in patients with advanced solid tumors who are relapsed/refractory to prior anti‑PD‑1/PD‑L1 therapy, with sites enrolling in Europe and the United States. CatalYm plans to use new funding to accelerate and expand the Phase 2 program and move visugromab toward pivotal studies. The company reported first Phase 2 data readouts expected in early 2023. Financially, CatalYm closed an oversubscribed EUR 50 million Series C to support these clinical plans. CatalYm develops monoclonal antibodies designed to overcome tumor immune suppression by neutralizing GDF-15, a protein that helps tumors evade the immune system. Its lead candidate, CTL-002, targets GDF-15 to enhance immune-cell infiltration, improve dendritic-cell priming of T cells, and boost T-cell and NK-cell tumor killing. CTL-002 is planned for development both as a monotherapy and in combination with approved PD-1/PD-L1 antagonists in checkpoint-blocker refractory patients. The company was founded in 2016 as a spin‑off from Julius‑Maximilians‑University of Würzburg and is led by CEO Dr. Manfred Rüdiger and CSO Christine Schuberth‑Wagner. CatalYm has backing from international venture investors and received support from the EIF via the EIB‑EIF Co‑investment Facility backed by the European Fund for Strategic Investments. The company recently closed a €50m Series B financing to advance its clinical development.

Led · Series C · Jul 2024

HepaRegeniX GmbH is a Tuebingen, Germany–based clinical-stage biopharma developing orally available small-molecule therapies that stimulate rapid liver regeneration. Its lead candidate, HRX-215, selectively inhibits MKK4 and is being developed to prevent post-hepatectomy liver failure, enable transplantation with smaller living donor grafts, and treat severe alcohol-associated hepatitis. HRX-215 is currently in a combined Phase Ib/IIa trial, and the company plans to use new funding to complete Phase Ib and advance the Phase IIa study. Beyond HRX-215, HepaRegeniX is developing HRX-233 to overcome kinase inhibitor resistance in KRAS-driven tumors. The company is led by CEO Elias Papatheodorou and has demonstrated safety of HRX-215 in clinical trials to date. HepaRegeniX raised €21.5M to support these clinical development milestones. HepaRegeniX is developing novel regenerative therapies targeting acute and chronic liver diseases based on inhibition of Mitogen-Activated Protein Kinase Kinase 4 (MKK4). The company has discovered multiple drug candidates centered on this proprietary molecular target. Its lead candidate, the MKK4 inhibitor HRX-215, recently completed Phase 1 clinical testing. HepaRegeniX intends to use the new funding to advance the clinical development of HRX-215. The company operates from Tuebingen, Germany and focuses on unlocking hepatocyte regenerative capacity even in severely diseased livers by suppressing MKK4. Recent financing strengthens its runway for upcoming clinical work. HepaRegeniX is a preclinical-stage company focused on developing a novel therapy for acute and chronic liver diseases. The company’s lead approach targets Mitogen-Activated Protein Kinase 4 (MKK4), a key regulator of liver regeneration. Suppression of MKK4 is reported to unlock the regenerative capacity of hepatocytes even in severely diseased livers. The therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. Led by CEO Dr. Michael Lutz, HepaRegeniX has discovered and developed several preclinical drug candidates based on this proprietary molecular target. The company closed an over €11M Series B and intends to use the funds to advance its MKK4 inhibitor into clinical testing later in 2020. HepaRegeniX GmbH is developing a therapeutic approach targeting liver regeneration by inhibiting MKK4. The company has acquired worldwide exclusive rights to the related IP discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. In collaboration with the Zender group and the medicinal chemistry group of Eberhard‑Karls University of Tübingen, HepaRegeniX has identified its first small‑molecule MKK4 inhibitors. The company plans to use the Series A proceeds to advance medicinal chemistry discovery programs and preclinical development of drug candidates through IND filing. Management, led by CEO Dr. Wolfgang Albrecht, is targeting a first clinical study for the treatment of acute liver failure in 2019. The company completed a €9m Series A financing to fund these efforts.